From the American Academy of Ophthalmology

This double-masked, sham-controlled study evaluated use of low-voltage, external-beam, stereotactic radiotherapy (SRT) as an adjunctive treatment  in 230 wet AMD patients randomized to receive PRN ranibizumab plus either 16 Gy, sham 16 Gy, 24 Gy, or sham 24 Gy. At 52 weeks, patients in the 16-Gy and 24-Gy SRT arms required fewer retreatments than those in the sham arms—2.64 (median, 2), 2.43 (median, 2), and 3.74 (median, 3.5), respectively. Structural and functional outcomes were encouraging.  Incidence of adverse events was similar across all treatment arms, with none attributable to radiation. Ophthalmology, September 2013